Breathe Well Live Well
Conditions: Moderate Persistent Asthma; Severe Persistent Asthma; Nodule Solitary Pulmonary; Pulmonary Atelectasis
Intervention: Procedure: Bronchial biopsy
Sponsor: Lu Yuan Lee
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Conditions: Asthma, Allergic; Rhinitis,Allergic; Allergy
Interventions: Drug: Azelastine-Fluticasone Nasal; Drug: Placebos
Sponsor: University of Dundee
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Drug: Reslizumab; Drug: Fludeoxyglucose F 18 (FDG); Drug: Placebo
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Conditions: Asthma; Pulmonary Disease, Chronic Obstructive
Intervention:
Sponsors: University of Leicester; University Hospitals, Leicester
Recruiting – verified August 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Intervention: Other: Smoking
Sponsors: Université de Montréal; Teva Pharmaceuticals USA
Not yet recruiting – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
[Lipid derivative of benzylidene malononitrile AG490 attenuates airway inflammation of mice with neutrophilic asthma].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 Jun;32(6):730-733
Authors: Zhang M, Nong G, Jiang M, Zhan W
Abstract
Objective To observe the effect of lipid derivative of benzylidene malononitrile AG490 on the airway inflammation in a mouse model of neutrophilic asthma (NA). Methods Fifty-four specific pathogen-free (SPF) female C57BL/6 mice were randomly divided into 3 groups: NA group, AG490-treated NA (NAAG) group, and normal control (NC) group, 18 mice in each group. The NA group and the NAAG group were sensitized by airway instillation of ovalbumin (OVA) and lipopolysaccharide (LPS) on day 0, 6 and 13. The NAAG group was injected with AG490 (500 ?g/mouse, i.p.) three times a week, from day 0 after the first sensitization, for 3 weeks. Mice were challenged on day 21, 22 for 1 hour/time with an aerosol of 10 g/L OVA. At 24 hours after the final challenge, bronchoalveolar lavage fluid (BALF) was collected. The total number and differential counts of nucleated cells and the percentage of each type were determined. HE staining and PAS staining was employed for observing the lung pathological changes. The percentages of Th17 cells and regulatory T cells (Treg) in the lung issue were determined by flow cytometry. The level of interleukin-17 (IL-17) in BALF was measured using ELISA. Results Compared with the NA group, the total number of nucleated cells, the percentage of neutrophils and the percentage of eosinophils in BALF in the NAAG group were obviously reduced; lung tissue pathologic changes were improved in the NAAG group; goblet cell hyperplasia and the level of IL-17 in BALF in the NAAG group were significantly down-regulated; the proportion of Treg in the lung increased and the proportion of Th17 cells in the lung decreased in the NAAG group. Conclusion After NA mice are treated with AG490 during the sensitization phase, the proportion of Treg in the lung would increase and the proportion of Th17 cells in the lung would decrease. AG490 could attenuate the airway inflammation in the mouse model of NA.
PMID: 27371836 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Condition: Asthma
Intervention: Dietary Supplement: coconut oil
Sponsors: Brigham and Women’s Hospital; Harvard School of Public Health
Not yet recruiting – verified June 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
 |
Abietic acid attenuates allergic airway inflammation in a mouse allergic asthma model.
Int Immunopharmacol. 2016 Jun 16;38:261-266
Authors: Gao Y, Zhaoyu L, Xiangming F, Chunyi L, Jiayu P, Lu S, Jitao C, Liangcai C, Jifang L
Abstract
Abietic acid (AA), one of the terpenoids isolated from Pimenta racemosa var. grissea, has been reported to have anti-inflammatory and immunomodulatory effects. However, the anti-allergic effects of AA remain unclear. The aim of this study was to investigate the anti-allergic effects of AA in an ovalbumin (OVA)-induced asthma murine model. The model of mouse asthma was established by induction of OVA. AA (10, 20, 40mg/kg) was administered by oral gavage 1h after the OVA treatment on days 21 to 23. At 24h after the last challenge, bronchoalveolar lavage fluid (BALF) and lung tissues were collected to assess pathological changes, cytokines production, and NF-?B expression. The results showed that AA attenuated lung histopathologic changes, inflammatory cells infiltration, and bronchial hyper-responsiveness. AA also inhibited OVA-induced the nitric oxide (NO), IL-4, IL-5, IL-13, and OVA-specific IgE production, as well as NF-?B activation. In conclusion, the current study demonstrated that AA exhibited protective effects against OVA-induced allergic asthma in mice and the possible mechanism was involved in inhibiting NF-?B activation.
PMID: 27318791 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
|
The asthma–COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway …
Dove Medical Press Abstract: The term asthma–COPD overlap syndrome (ACOS) is one of multiple terms used to describe patients with characteristics of both COPD and asthma, representing ~20% of patients with obstructive airway diseases. The recognition of both sets of … |
View full post on asthma – Google News
Condition: Asthma
Intervention:
Sponsor: University of California, San Francisco
Not yet recruiting – verified June 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days